MedTrace Logo

Tibial Nerve and Extracorporeal Magnetic Stimulation for Overactive Bladder

NCT05387824 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2022-11-01

No results posted yet for this study

Summary

Overactive bladder (OAB) syndrome is urinary urgency, usually accompanied by frequency and nocturia, with or without urgency urinary incontinence, in the absence of urinary tract infection. For the treatment of OAB; pharmacological and non-pharmacological methods are available. The availability and the continuation rate of pharmacological treatments are lower than non-pharmacological treatments due to side effects.

Non-pharmacologic treatment methods are evaluated in two groups as active and passive methods. Active methods which active participation of the patient is required during treatment are Pelvic floor muscle exercise (PFME), biofeedback assisted PFME, vaginal cones, while passive methods are Electrical Stimulation, extracorporeal Magnetic Stimulation (MStim) and Transcutaneous Tibial Nerve Stimulation (TTNS) techniques.

In this study, investigators aim to evaluate the effectiveness of TTNS and extracorporeal MStim, which are noninvasive methods, added to bladder training (BT) in women with OAB, with a prospective randomized controlled research method.

Conditions

  • Idiopathic Overactive Bladder
  • Bladder Training
  • Transcutaneous Tibial Nerve Stimulation
  • Magnetic Stimulation

Interventions

DEVICE

Magnetic stimulation -Armchair type MS • NovaMag NT-60

MS was applied two days a week, 20 minutes a day, a total of 12 sessions for 6 weeks.

DEVICE

Electrical Stimulation- TTNS

TTNS were performed 2 days a week, for 30 min a day, for a total of 12 sessions for 6 weeks.

BEHAVIORAL

Bladder Training

Control group All women were informed about BT for 30 minutes. Then it was given as a written brochure to be implemented as a home program. BT, consisting of four stages, did not contain any PFMT programs in two groups.

Sponsors & Collaborators

  • Pamukkale University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-06-02
Primary Completion
2022-10-29
Completion
2022-11-15

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05387824 on ClinicalTrials.gov